Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Principia Biopharma discloses new protein kinase inhibitors

Dec. 20, 2012

Interim safety results reported from phase IIa study of stem cell therapy in RA

Dec. 19, 2012

FX-006 achieves prolonged therapeutic concentrations in osteoarthritis

Dec. 19, 2012

Invion reports on pre-IND meeting for INV-103

Dec. 18, 2012

Lilly stops one of three phase III tabalumab trials in rheumatoid arthritis

Dec. 17, 2012

AstraZeneca reports on OSKIRA-4 phase IIb fostamatinib study

Dec. 14, 2012

Fred Hutchinson and GSK partner to develop muscular dystrophy therapeutics

Dec. 13, 2012

ONO-4059 demonstrates inhibition of arthritis severity and bone damage in vivo

Dec. 12, 2012

Results of first-in-human study of NNC-0114-0005 reported

Dec. 10, 2012

Genentech presents phase II results for rontalizumab in patients with SLE

Dec. 10, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...